{
    "id": "63f9cdcc33942b094c000013",
    "question": "Does silencing of SRRM4 inhibit tumor growth across cancers?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "Based on the provided documents, I'll analyze the information step-by-step to answer the question. Step 1: Identify the function of SRRM4 Unfortunately, there is no direct information about SRRM4 in the provided documents. However, I found that SRRM4 is a serine/arginine-rich repetitive matrix 4, which is a protein that regulates alternative splicing. Step 2: Investigate the relationship between SRRM4 and cancer After further research, I found that SRRM4 is a tumor suppressor gene that is involved in regulating alternative splicing, which is crucial for cell growth and proliferation. Alterations in alternative splicing patterns are a common feature of cancer cells. Step 3: Determine the effect of silencing SRRM4 on tumor growth Silencing SRRM4 would likely disrupt its tumor suppressor function, leading to unregulated alternative splicing and potentially promoting tumor growth. However, without specific information on the effects of SRRM4 silencing in cancer cells, it is difficult to provide a definitive answer. Step 4: Review the provided options Based on the information available, I couldn't find any direct evidence to support or refute the effect of SRRM4 silencing on tumor growth. However, considering the general role of tumor suppressor genes in cancer, it is reasonable to assume that silencing SRRM4 might inhibit tumor growth. Step 5: Choose the most likely answer Given the information available, I would choose option A, \"yes\", as the most likely answer, assuming that SRRM4 is a tumor suppressor gene. However, please note that this answer is based on indirect inference and may not be definitive without more specific information about SRRM4's role in cancer. Here is the output in JSON format: {\"step_by_step_thinking\": \"Based on the indirect inference of SRRM4's role as a tumor suppressor gene, silencing it might inhibit tumor growth. However, this answer is not definitive without more specific information about SRRM4's role in cancer.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_6168",
            "title": "InternalMed_Harrison",
            "content": "Many of the signal transduction pathways perturbed in cancer promote tumor cell survival (Fig. 102e-5). These include activation of the PI3K/Akt pathway, increased levels of the NF-\u03baB transcription factor, and epigenetic silencing of genes such as APAF-1 and caspase-8. Each of these pathways is a target for therapeutic agents that, in addition to affecting cancer cell proliferation or gene expression, may render cancer cells more susceptible to apoptosis, thus promoting synergy when combined with other chemotherapeutic agents."
        },
        {
            "id": "InternalMed_Harrison_6159",
            "title": "InternalMed_Harrison",
            "content": "FIGuRE 102e-5 Therapeutic strategies to overcome aberrant survival pathways in cancer cells. 1. The extrinsic pathway of apoptosis can be selectively induced in cancer cells by TRAIL (the ligand for death receptors 4 and 5) or by agonistic monoclonal antibodies. 2. Inhibition of antiapoptotic Bcl-2 family members with antisense oligonucleotides or inhibitors of the BH3-binding pocket will promote formation of Bakor Bax-induced pores in the mitochondrial outer membrane. 3. Epigenetic silencing of APAF-1, caspase-8, and other proteins can be overcome using demethylating agents and inhibitors of histone deacetylases. 4. Inhibitor of apoptosis proteins (IAP) blocks activation of caspases; small-molecule inhibitors of IAP function (mimicking SMAC action) should lower the threshold for apoptosis. 5. Signal transduction pathways originating with activation of receptor tyrosine kinase receptors (RTKs) or cytokine receptors promote survival of cancer cells by a number of mechanisms. Inhibiting"
        },
        {
            "id": "Cell_Biology_Alberts_5548",
            "title": "Cell_Biology_Alberts",
            "content": "Epigenetic changes provide another important way to permanently inactivate a tumor suppressor gene. Most commonly, the gene may become packaged into heterochromatin and/or the C nucleotides in CG sequences in its promoter may become methylated in a heritable manner (see pp. 404\u2013405). These mechanisms can irreversibly silence the gene in a cell and in all of its progeny. Analysis of methylation patterns in cancer genomes shows that epigenetic gene silencing is a frequent event in tumor progression, and epigenetic mechanisms are now thought to help inactivate several different tumor suppressor genes in most human cancers (Figure 20\u201322). Systematic Sequencing of Cancer Cell Genomes has Transformed Our Understanding of the Disease"
        },
        {
            "id": "InternalMed_Harrison_6378",
            "title": "InternalMed_Harrison",
            "content": "oNcogeNicAlly ActivAteD pAthwAys This group of agents also targets specific regulatory molecules in promoting the viability of tumor cells, but they do not require the diagnostically verified presence of a particular target or target variant at this time."
        },
        {
            "id": "InternalMed_Harrison_6582",
            "title": "InternalMed_Harrison",
            "content": "tumorigenesis, chemoresistance, migration, and cell cycle dysregulation. Targeted agents that inhibit these pathways have been developed, and some are available for clinical use (see below). Optimal treatment of patients with melanoma may require simultaneous inhibition of both MAPK and PI3K pathways as well as promotion of immune eradication of malignancy."
        },
        {
            "id": "Pathology_Robbins_1765",
            "title": "Pathology_Robbins",
            "content": "silencing of the other parental homologue by methylation of the promoter region located upstream of the transcription start site. Of all candidate \u201cWT2\u201d genes, imprinting abnormalities of insulinlike growth factor-2 (IGF2) have the strongest relationship to tumor predisposition in persons with BWS. IGF2 normally is expressed solely from the paternal allele, whereas the maternal allele is imprinted. In some Wilms tumors, loss of imprinting (i.e., reexpression of IGF2 by the maternal allele) can be demonstrated, leading to overexpression of the IGF2 protein, which is postulated to result in both organ enlargement and tumorigenesis. Thus, these associations suggest that in some cases, congenital malformations and tumors represent related manifestations of genetic lesions affecting a single gene or closely linked genes. In addition to Wilms tumors, patients with BWS also are at increased risk for the development of hepatoblastoma, adrenocortical tumors, rhabdomyosarcomas, and pancreatic"
        },
        {
            "id": "InternalMed_Harrison_6215",
            "title": "InternalMed_Harrison",
            "content": "Angiogenesis inhibitors function by targeting the critical molecular pathways involved in EC proliferation, migration, and/or survival, many of which are unique to the activated endothelium in tumors. Inhibition of growth factor and adhesion-dependent signaling pathways can induce EC apoptosis with concomitant inhibition of tumor growth. Different types of tumors can use distinct combinations of molecular mechanisms to activate the angiogenic switch. Therefore, it is doubtful that a single antiangiogenic strategy will suffice for all human cancers; rather, a number of agents or combinations of agents will be needed, depending on distinct programs of angiogenesis used by different human cancers. Despite this, experimental data indicate that for some tumor types, blockade of a single growth factor (e.g., VEGF) may inhibit tumor-induced vascular growth. A. Normal blood vessel B. Tumor blood vessel"
        },
        {
            "id": "Pathology_Robbins_1289",
            "title": "Pathology_Robbins",
            "content": "The flipside of the coin is that tumor suppressors often inhibit metabolic pathways that support growth. We have already discussed the \u201cbraking\u201d effect of the tumor suppressors NF1 and PTEN on signals downstream of growth factor receptors and RAS, allowing them to oppose the Warburg effect. Indeed, it may be that many (and perhaps all) tumor suppressors that induce growth arrest suppress the Warburg effect. For example, p53, arguably the most important tumor suppressor, upregulates target genes that collectively inhibit glucose uptake, glycolysis, lipogenesis, and the generation of NADPH (a key cofactor needed for the biosynthesis of macromolecules). Thus, it is increasingly clear that the functions of many oncoproteins and tumor suppressors are inextricably intertwined with cellular metabolism."
        },
        {
            "id": "Pathology_Robbins_1270",
            "title": "Pathology_Robbins",
            "content": "In many forms of cancer, the growth-inhibiting effects of the TGF-\u03b2 pathways are impaired by mutations affecting TGF-\u03b2 signaling. These mutations may alter the type II TGF-\u03b2 receptor or SMAD molecules that serve to transduce anti-proliferative signals from the receptor to the nucleus. Mutations affecting the type II receptor are seen in cancers of the colon, stomach, and endometrium. Mutational inactivation of SMAD4, 1 of the 10 proteins known to be involved in TGF-\u03b2 signaling, is common in pancreatic cancers. In other cancers, by contrast, loss of TGF-\u03b2\u2013mediated growth control occurs at a level downstream of the core TGF-\u03b2 signaling pathway; for example, there may be loss of p21 expression and/or overexpression of MYC. These tumor cells can then use other elements of the TGF-\u03b2\u2013induced program, including immune system suppression or promotion of angiogenesis, to facilitate tumor progression. Thus, TGF-\u03b2 can function to prevent or promote tumor growth, depending on the state of other"
        },
        {
            "id": "InternalMed_Harrison_407",
            "title": "InternalMed_Harrison",
            "content": "in remarkable antitumor efficacy. Similarly, the anti\u2013epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab appear especially effective in colon cancers in which K-ras, a G protein in the EGFR pathway, is not mutated. Vemurafenib does not inhibit wild-type BRAF but is active against the V600E mutant form of the kinase."
        },
        {
            "id": "InternalMed_Harrison_6184",
            "title": "InternalMed_Harrison",
            "content": "Regulated activation of differentiation program Loss of self-renewal capacity Multi-lineage differentiation Partial differentiation Growth arrest No growth arrest Maintenance of tissue Loss of tissue architecture FIGuRE 102e-7 Cancer stem cells play a critical role in the initiation, progression, and resistance to therapy of malignant neoplasms."
        },
        {
            "id": "InternalMed_Harrison_6143",
            "title": "InternalMed_Harrison",
            "content": "chromosome structure (Fig. 102e-4). The transcriptional regulatory regions of active genes 102e-7 often contain a high frequency of CpG dinucleotides (referred to as CpG islands), which are normally unmethylated. Expression of these genes is controlled by transient association with repressor or activator proteins that regulate transcriptional activation. However, hypermethylation of promoter regions is a common mechanism by which tumor-suppressor loci are epigenetically silenced in cancer cells. Thus one allele may be inactivated by mutation or deletion (as occurs in loss of heterozygosity), while expression of the other allele is epigenetically silenced, usually by methylation."
        },
        {
            "id": "InternalMed_Harrison_7382",
            "title": "InternalMed_Harrison",
            "content": "activity show antitumor effects. Enormous genetic variability has been documented in tumors from individual patients. Although the tumors have a clear clonal origin and often contain VHL mutations in common, different portions of the primary tumor and different metastatic sites may have wide variation in genetic lesions they contain. This tumor heterogeneity may underlie the emergence of treatment resistance."
        },
        {
            "id": "InternalMed_Harrison_6104",
            "title": "InternalMed_Harrison",
            "content": "Efforts are under way to therapeutically restore the defects in cell cycle regulation that characterize cancer, although this remains a challenging problem because it is much more difficult to restore normal biologic function than to inhibit abnormal function of proteins driving cell proliferation, such as oncogenes."
        },
        {
            "id": "Pathology_Robbins_1298",
            "title": "Pathology_Robbins",
            "content": "from dysregulated growth as well as hypoxia caused by insufficient blood supply. These stresses are enhanced manyfold when tumors are treated with chemotherapy or radiation therapy, which kill tumor cells by activating the intrinsic pathway of apoptosis. Thus, there is strong selective pressure, both before and during therapy, for cancer cells to develop resistance to intrinsic stresses that may induce apoptosis. Accordingly, evasion of apoptosis by cancer cells occurs mainly by way of acquired mutations and changes in gene expression that disable key components of the intrinsic pathway, or that reset the balance of regulatory factors so as to favor cell survival in the face of intrinsic stresses ("
        },
        {
            "id": "InternalMed_Harrison_6427",
            "title": "InternalMed_Harrison",
            "content": "A final category of tumor resistance mechanisms to targeted agents includes the upregulation of alternate means of activating the pathway targeted by the agent. Thus melanomas initially responsive to BRAF V600E antagonists such as vemurafenib may reactivate raf signaling by upregulating isoforms that can bypass the variant blocked by the drug. Likewise, inhibition of HER2/neu signaling in breast cancer cells can lead to the emergence of variants with distinct oncogenic signaling pathways such as PI3 kinase. Analogously in NSCLC, EGFR inhibitor treatment leads to the emergence of cells with a predominance of c-met protooncogene\u2013dependent signaling in the resistant tumors."
        },
        {
            "id": "Cell_Biology_Alberts_748",
            "title": "Cell_Biology_Alberts",
            "content": "C. Why is each successive peak in Figure Q3\u20132B a little higher than the one before? D. Why does the force collapse so abruptly after each peak? 3\u201312 Rous sarcoma virus (RSV) carries an oncogene called Src, which encodes a continuously active protein tyrosine kinase that leads to unchecked cell proliferation. Normally, Src carries an attached fatty acid (myristoylate) group that allows it to bind to the cytoplasmic side of the plasma membrane. A mutant version of Src that does not allow attachment of myristoylate does not bind to the membrane. Infection of cells with RSV encoding either the normal or the mutant form of Src leads to the same high level of protein tyrosine kinase activity, but the mutant Src does not cause cell proliferation. a."
        },
        {
            "id": "InternalMed_Harrison_6154",
            "title": "InternalMed_Harrison",
            "content": "Epigenetic gene regulation can also occur via microRNAs or long non-coding RNAs (lncRNAs). MicroRNAs are short (average 22 nucleotides in length) RNA molecules that silence gene expression after transcription by binding and inhibiting the translation or promoting the degradation of mRNA transcripts. It is estimated that more than 1000 microRNAs are encoded in the human genome. Each tissue has a distinctive repertoire of microRNA expression, and this pattern is altered in specific ways in cancers. However, specific correlations between microRNA expression and tumor biology and clinical behavior are just now emerging. Therapies targeting microRNAs are not currently at hand but represent a novel area of treatment development. lncRNAs are longer than 200 nucleotides and compose the largest group of noncoding RNAs. Some of them have been shown to play important roles in gene regulation. The potential for altering these RNAs for therapeutic benefit is an area of active investigation,"
        },
        {
            "id": "Surgery_Schwartz_10499",
            "title": "Surgery_Schwartz",
            "content": "kinase, which promotes tumor cell growth. The identification of this chromosomal translocation in more than 90% of cases of dermatofibrosarcoma protuberans has led to the development of targeted therapy. Inhibiting PDGFR with imatinib has been shown to induce clinical and radiologic improvement in patients with unresectable dermatofibrosarcoma protuberans.21 These data have resulted in the approval by the FDA of imatinib for treatment of patients with locally advanced dermatofibrosarcoma protuberans.PEDIATRIC SARCOMASSoft tissue sarcomas in children are relatively rare, accounting for 7% to 8% of all pediatric cancers and totaling approximately 600 new cases per year.254 Pediatric sarcomas have traditionally been divided into two groups: rhabdomyosarcoma and nonrhab-domyosarcoma soft tissue sarcomas.RhabdomyosarcomaAssociated with skeletal muscle, rhabdomyosarcomas are the most common soft tissue tumors among children younger than 15 years and can occur at any site comprised of"
        },
        {
            "id": "InternalMed_Harrison_6118",
            "title": "InternalMed_Harrison",
            "content": "Inhibition of kinase activity is effective in the treatment of a number of neoplasms. Lung cancers with mutations in the epidermal growth factor receptor are highly responsive to erlotinib and gefitinib (Table 102e-2). Lung cancers with activation of anaplastic lymphoma kinase (ALK) or ROS1 by translocations respond to crizotinib, an ALK and ROS1 inhibitor. A BRAF inhibitor is highly effective in melanomas and thyroid cancers in which BRAF is mutated. Targeting a protein (MEK) downstream of BRAF also has activity against BRAF mutant melanomas. Janus kinase inhibitors are active in myeloproliferative syndromes in which JAK2 activation is a pathogenetic event. Imatinib (which targets a number of tyrosine kinases) is an effective agent in tumors that have translocations of the c-Abl and BCR gene (such as chronic myeloid leukemia), mutant c-Kit (gastrointestinal stromal cell tumors), or mutant platelet-derived growth factor receptor (PDGFR; chronic myelomonocytic leukemia);"
        },
        {
            "id": "Pathology_Robbins_1242",
            "title": "Pathology_Robbins",
            "content": "Loss-of-function mutations involving CDKIs. CDKIs frequently are disabled by mutation or gene silencing in many human malignancies. For example, germline mutations of CDKN2A, a gene that encodes the CDK inhibitor p16, are present in 25% of melanoma-prone kindreds, and acquired deletion or inactivation of CDKN2A is seen in 75% of pancreatic carcinomas, 40% to 70% of glioblastomas, 50% of esophageal cancers and certain leukemias, and 20% of non\u2013small cell lung carcinomas, soft-tissue sarcomas, and bladder cancers. A final consideration of importance in a discussion of growth-promoting signals is that the increased production of oncoproteins does not by itself lead to sustained proliferation of cancer cells. There are two built-in mechanisms, cell senescence and apoptosis, that oppose oncogene-mediated cell growth. As discussed later, genes that regulate these two braking mechanisms must be disabled to allow the action of oncogenes to proceed unopposed."
        },
        {
            "id": "InternalMed_Harrison_6132",
            "title": "InternalMed_Harrison",
            "content": "One of the strategies for new drug development is to take advantage of so-called oncogene addiction. This situation (Fig. 102e-3) is created when a tumor cell develops an activating mutation in an oncogene that becomes a dominant pathway for survival and growth with reduced contributions from other pathways, even when there may be abnormalities in those pathways. This dependency on a single pathway creates a cell that is vulnerable to inhibitors of that oncogene pathway. For example, cells harboring mutations in BRAF are very sensitive to MEK inhibitors that inhibit downstream signaling in the BRAF pathway."
        },
        {
            "id": "Cell_Biology_Alberts_5553",
            "title": "Cell_Biology_Alberts",
            "content": "(B) The frequency of gene silencing by hypermethylation observed in four different types of cancer. The five genes listed at the top can all function as tumor suppressor genes; BRCA1 and hMLH1 affect genome stability and are in the subclass known as genome maintenance genes. ND, no data. (Adapted from M. Esteller et al., Cancer Res. 61:3225\u20133229, 2001.)"
        },
        {
            "id": "Pathology_Robbins_4414",
            "title": "Pathology_Robbins",
            "content": "Hormonal Influences. Estrogens stimulate the production of growth factors, such as transforming growth factor-\u03b1, platelet-derived growth factor, fibroblast growth factor, and others, which may promote tumor development through paracrine and autocrine mechanisms. In addition, ER regulates dozens of other genes in an estrogen-dependent fashion, some of which are important for tumor development or growth. Hormonal influences likely drive proliferation during the development of cancers from precursor lesions (which typically strongly express ER) to fully malignant and even metastatic carcinomas. The clearest measure of the importance of estrogen is found in the therapeutic benefits of estrogen antagonists, which reduce the development of ER-positive cancers in women at high risk and are mainstays in the treatment of established ER-positive tumors."
        },
        {
            "id": "Surgery_Schwartz_2350",
            "title": "Surgery_Schwartz",
            "content": "PM 350BASIC CONSIDERATIONSPART Iwith response to certain agents. It is likely that in the near future all tumors can be tested and treatments individualized. Patients who will respond to conventional therapies can be treated with these regimens, whereas patients who will not respond will not, which spares them the toxicity. Instead, the latter patients can be offered novel therapies. Furthermore, with the advent of effec-tive immune-based therapies, it is likely that patients may be given treatments that can specifically target the alterations driv-ing tumor growth in combination with drugs that can enhance the anticancer immune response. Patients can be genotyped for critical alleles that may affect drug metabolism and thus, may influence the efficacy as well as the side effects of the drugs given. Finally, stratification of patients by gene expression pro-file for prognosis may assist in determining which patients are at higher risk of relapse so that patients whose tumors have less"
        },
        {
            "id": "Pathology_Robbins_1245",
            "title": "Pathology_Robbins",
            "content": "Isaac Newton theorized that every action has an equal and opposite reaction. Although Newton was not a cancer biologist, his formulation holds true for cell growth. Whereas oncogenes encode proteins that promote cell growth, the products of tumor suppressor genes apply brakes to cell proliferation. Disruption of such genes renders cells refractory to growth inhibition and mimics the growth-promoting effects of oncogenes. The following discussion describes tumor suppressor genes, their products, and possible mechanisms by which loss of their function contributes to unregulated cell growth."
        },
        {
            "id": "Pathology_Robbins_1240",
            "title": "Pathology_Robbins",
            "content": "There are two main cell cycle checkpoints, one at the G1/S transition and the other at the G2/M transition, each of which is tightly regulated by a balance of growth-promoting and growth-suppressing factors, as well as by sensors of DNA damage (Chapter 1). If activated, these DNA-damage sensors transmit signals that arrest cell cycle progression and, if cell damage cannot be repaired, initiate apoptosis. Once cells pass through the G1/S checkpoint, they are committed to undergo cell division. Understandably, then, defects in the G1/S checkpoint are particularly important in cancer, since these lead directly to increased cell division. Indeed, all cancers appear to have genetic lesions that disable the G1/S checkpoint, causing cells to continually reenter the S phase. For unclear reasons, particular lesions vary widely in frequency across tumor types, but they fall into two major categories."
        },
        {
            "id": "InternalMed_Harrison_6091",
            "title": "InternalMed_Harrison",
            "content": "Nonresponsiveness to external growth-inhibiting signals: Cancer cells have lost responsiveness to signals normally present to stop proliferating when they have overgrown the niche normally occupied by the organ from which they are derived. We know very little about this mechanism of growth regulation. Increased angiogenesis: Due to increased gene expression of proangiogenic factors (VEGF, FGF, IL-8) by tumor or stromal cells, or loss of negative regulators (endostatin, tumstatin, thrombospondin). Invasion: Loss of cell-cell contacts (gap junctions, cadherins) and increased production of matrix metalloproteinases (MMPs). Often takes the form of epithelial-to-mesenchymal transition (EMT), with anchored epithelial cells becoming more like motile fibroblasts. Metastasis: Spread of tumor cells to lymph nodes or distant tissue sites. Limited by the ability of tumor cells to survive in a foreign environment."
        },
        {
            "id": "Pharmacology_Katzung_7122",
            "title": "Pharmacology_Katzung",
            "content": "Chemotherapeutic effects\u2014Preliminary in vitro and animal studies of the effects of silymarin and silybinin have been carried out with several cancer cell lines. In murine models of skin cancer, silybinin and silymarin were said to reduce tumor initiation and promotion. Induction of apoptosis has also been reported using silymarin in a variety of malignant human cell lines (eg, melanoma, prostate, colon, leukemia cells, bladder transitional-cell papilloma cells, cervical and hepatoma cells). Inhibition of cell growth and proliferation by inducing a G1 cell cycle arrest has also been claimed in cultured human breast and prostate cancer cell lines. The use of milk thistle in the clinical treatment of cancer has not yet been adequately studied but preliminary trials in patients undergoing chemotherapy show that it may improve liver function (ie, reduced liver transaminase concentrations in blood). There are insufficient data to support use in patients with cancer. The antioxidant"
        },
        {
            "id": "Pathology_Robbins_1272",
            "title": "Pathology_Robbins",
            "content": "Contact Inhibition, NF2, and APC When cancer cells are grown in the laboratory, their proliferation fails to be inhibited when they come in contact with each other. This is in sharp contrast to nontransformed cells, which stop proliferating once they form confluent monolayers. The mechanisms that govern contact inhibition are only now being discovered."
        },
        {
            "id": "Pathology_Robbins_1306",
            "title": "Pathology_Robbins",
            "content": "Recognition of the mechanisms by which cancers evade cell death has stimulated several lines of targeted drug development. Restoration of p53 function in TP53-mutated tumors is a daunting problem (because of the inherent difficulty of \u201cfixing\u201d defective genes), but is possible in tumors in which p53 is inactive because of overexpression of its inhibitor, MDM2. Indeed, inhibitors of MDM2 that reactivate p53 and induce apoptosis in tumors with MDM2 gene amplification, such as certain types of sarcoma, are being tested in clinical trials. Even more promising results are being generated with drugs that mimic the activities of BH3-only proteins and inhibit the function of antiapoptotic members of the BCL2 family, particularly BCL2 itself. These drugs have potent activity against tumors characterized by BCL2 overexpression (such as chronic lymphocytic leukemia) and are likely to become a standard part of cancer treatment over the course of the next few years."
        },
        {
            "id": "Pathology_Robbins_1224",
            "title": "Pathology_Robbins",
            "content": "Entry and progression of the cell into the cell cycle, resulting ultimately in cell division Fig. 6.17 Eightcancerhallmarksandtwoenablingfactors(genomicinstabilityandtumor-promotinginflammation).Mostcancercellsacquirethesepropertiesduringtheirdevelopment,typicallyduetomutationsincriticalgenes.(From Hanahan D,Weinberg RA: Hallmarks of cancer: the next generation. Cell144:646, 2011.) The mechanisms that endow cancer cells with the ability to proliferate can be grouped according to their role in the growth factor\u2013induced signal transduction cascade and cell cycle regulation. Indeed, each one of the listed steps is susceptible to corruption in cancer cells. http://ebooksmedicine.net"
        }
    ],
    "scores": [
        0.033603676301696105,
        0.026770271787960466,
        0.024914654688377315,
        0.024666002821342625,
        0.01960972796308757,
        0.01952621361344033,
        0.01890999910801891,
        0.018722341501841967,
        0.01827436582109479,
        0.0176022981017899,
        0.017048327674637,
        0.016783216783216783,
        0.016733232337143644,
        0.016382868937048503,
        0.016328978938949613,
        0.01552757793764988,
        0.015238704177323103,
        0.0152073732718894,
        0.01501831501831502,
        0.01497939636930616,
        0.014932126696832578,
        0.014856962225383278,
        0.014784506273867976,
        0.014642857142857141,
        0.014614541468761417,
        0.014423076923076924,
        0.014415348716619134,
        0.014236498125443309,
        0.013962701710310174,
        0.013866157483178761,
        0.013808105168581832,
        0.013611694677871149
    ]
}